

The information in this press release is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, South Africa, Switzerland or Singapore.

Press Release December 7, 2009

MPM Capital Shows Commitment and Full Support to Biovitrum Transactions

Stockholm, Sweden – Dec 7, 2009 – As the second biggest shareholder in Biovitrum AB (publ) (STO: BVT), MPM Capital ("MPM") publically expresses its full support of the combination with Swedish Orphan. The transaction has a very solid industrial logic and MPM want to contribute to the creation of a new niche specialty pharmaceutical company focused on rare diseases.

With its structure as manager of closed end private equity funds, it was not possible for MPM Capital to put in new capital into the upcoming rights issue, financing the Swedish Orphan transaction. MPM has therefore sold shares in Biovitrum over the last month, with the sole purpose of financing its participation in the upcoming rights issue. The proceeds from the sale will go into exercising rights. MPM now owns approximately 12.5% of the capital and votes in Biovitrum and this is a position that MPM will defend by subscribing in the rights issue.

About Biovitrum

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. Biovitrum has revenues of approximately SEK 1.2 billion and approximately 400 employees (prior to the Transaction). Biovitrum's head office is located in Sweden and the share is listed on the NASDAQ OMX Stockholm. For more information please visit www.biovitrum.com.

For more information please contact:

Biovitrum AB (publ)

Erik Kinnman, Vice President Investor Relations

Phone: +46 73 422 15 40

erik.kinnman@biovitrum.com

Martin Nicklasson, CEO

Phone. +46 8 697 23 27

IMPORTANT NOTICE:

The information in this press release is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, South Africa, Switzerland or Singapore. The information in this press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer,



solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

The information in this press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the "Securities Act"). The securities mentioned herein may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offer of securities in the United States.

The information in this press release may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

Biovitrum AB (publ) may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on December 7, 2009 at 3:30 p.m. CET.